1 / 52

Genital Herpes: Framing the Problem, Diagnosing the Disease

Genital Herpes: Framing the Problem, Diagnosing the Disease. Prevention and Management for Healthcare Providers. Genital Herpes: Epidemiology and Clinical Presentation. STDs are Sexist. Transmission efficiency greater male to female than the reverse

jescie-rodgers
Download Presentation

Genital Herpes: Framing the Problem, Diagnosing the Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Genital Herpes: Framing the Problem, Diagnosing the Disease Prevention and Management for Healthcare Providers

  2. Genital Herpes: Epidemiology and Clinical Presentation

  3. STDs are Sexist • Transmission efficiency greater male to female than the reverse • More women asymptomatic or with atypical, nonspecific symptoms; delayed care • Diagnosis more difficult in women • Complications more frequent in women, often severe or permanent

  4. Herpes Simplex Virus • Mucocutaneous infection, retrograde infection of sensory nerves, continuous slow replication (with clinical latency) in cranial or spinal ganglia and peripheral nerve endings, mucocutaneous recurrences • HSV-1 • Mostly orolabial (cold sores, fever blisters) • 20%-50% of initial genital herpes in North America and western Europe • HSV-2 • Almost entirely genital; oral infection uncommon • >90% of recurrent genital herpes

  5. Prevalence of Genital HSV Infection in Adults in the United States • HSV-2, NHANES-II (1978) 16% (15M age 15-49) • HSV-2, NHANES-III (1991) 22% (24M age 15-49) • HSV-2, NHANES 1999-2004 17% (27M age 15-49) • Genital HSV-1 infection 10 million (??) • TOTAL >20% >30 million ~30% Total 18 17 Xu F et al. JAMA. 2006;296:964-973.

  6. Perceived Trauma of ContractingGenital Herpes I'm going to read you a list of items that people may or may not consider traumatic. For each one I read, please tell me how traumatic it would be for you personally: very traumatic, somewhat traumatic, not very traumatic, or not traumatic at all. Percent Saying "Very Traumatic" Acquiring AIDS Having genital herpes Breaking up with a significant other Getting fired from a job Failing a course in school

  7. Genital Herpes and HIV Transmission • HSV-2 infection is the most important STD in enhancing HIV transmission efficiency; may account for up to half of all HIV infections • HSV-2 infected persons have 2–4x increased chance of acquiring HIV if sexually exposed • Persons with HIV and symptomatic genital herpes are more efficient HIV transmitters • HSV-2 serologic testing should be routine in persons with HIV or at high risk (men having sex with men, intravenous drug users, and their partners) [controversial]

  8. Relative Risk of HIV Acquisition in HSV-2 Positive vs HSV-2 Negative Persons Freeman EE et al. AIDS. 2006;20:73-83.

  9. Clinical Spectrum of Genital Herpes • First episode infection • Primary: First infection with HSV-1 or -2 (~20%) • Nonprimary first episode: Prior infection with the opposite HSV type (~40%) • First recognized episode of longstanding infection (~40%) • Recurrent infection: Second or subsequent outbreak (HSV-2 >> HSV-1) • Subclinical infection: ~60%–90% of infections • Truly asymptomatic • Unrecognized

  10. Clinical Manifestations of Genital Herpes • Initial infection • Vesiculopustular lesions (bilateral) • Cervicitis, urethritis • Lymphadenopathy • Neuropathic manifestations • Systemic inflammation (fever, etc) • Duration typically 2–4 weeks • Recurrent outbreaks • Unilateral lesions • Nonspecific symptoms (discharge, dysuria, etc) • Neuropathic prodrome • Duration 1–2 weeks • Common misdiagnoses • Vulvovaginal candidiasis and other vaginal infections • Syphilis, chancroid • Urinary tract infection • Genital trauma

  11. Biomedical Complications of HSV Infection • Localized neuropathies (eg, bladder paralysis) • Meningitis (isolated, recurrent) • Erythema multiforme, Stevens Johnson syndrome • Perinatal and maternal morbidity • Neonatal herpes • Cesarean section • Autoinoculation conjunctivitis, keratitis, whitlow • Chronic localized disease in immunodeficient patients (especially HIV/AIDS) • Enhanced HIV transmission • Rare disseminated infection, hepatic necrosis, death

  12. Mean recurrence rate in first year after initial genital HSV-2 infection (N = 457, median FU 391 days) Men 5.2 episodes/yr Women 4.0 episodes/yr >6 recurrences in first year 38% >10 recurrences in first year 20% Rate gradually declines over several years Recurrence after initial genital HSV-1 (N = 83) Mean recurrences 1.3 yr 1, 0.7 yr 2, & beyond 38% had no recurrences Recurrence Rate After Initial Genital Herpes Diamond C, et al. Sex Transm Dis. 1999;26:221-225. Engelberg R, et al. Sex Transm Dis. 2003;30:174-177.

  13. Oral HSV-1 Other infections ('cold sore,' 'fever blister') Actinic/ultraviolet injury Other local trauma (eg, surgery) Genital HSV-2 No clearly documented triggers No good data support stress, diet, menstruation, sex, etc, despite anecdotal reports and strongly held beliefs to the contrary What Triggers Recurrent Outbreaks?

  14. Asymptomatic Viral Shedding in Transmission and Acquisition of HSV-2 Peter A. Leone, MD Associate Professor of Medicine University of North Carolina Chapel Hill, North Carolina Medical Director North Carolina HIV/STD Prevention and Care Branch NCDHHS

  15. Asymptomatic Viral Shedding • Asymptomatic viral shedding (AVS) is the presence of HSV on the surface of the skin/mucosa in the absence of signs and symptoms[1-3] 1. Corey L, Wald A. Sex Transm Dis. 1999;285-312. 2. Wald A, et al. N Engl J Med. 1995;333:770-775. 3. Mertz GJ, et al. Ann Intern Med. 1992;116:197-202.

  16. Key Facts for Patients • Patients frequently spread GH between outbreaks[1] • Most patients shed virus asymptomatically*[2] • Patients cannot predict when AVS will occur[3] • All patients are at risk for AVS, regardless of outbreak frequency[3] • Recent data suggest shedding is a more continuous process than previously realized • Safer sex practices should be used • Even with safer sex , it is still possible to transmit HSV • Condoms cannot provide 100% protection against transmission, they do not cover all potential sites of HSV shedding *Shedding in the absence of lesions 1. Corey L, Wald A. Sex Transm Dis. 1999:285-312. 2. Wald A, et al. N Engl J Med. 1995;333:770-775. 3. Mertz GJ, et al. Ann Intern Med. 1992;116:197-202.

  17. Asymptomatic Viral Shedding Is Common and Can Occur Frequently • Most GH patients experience asymptomatic shedding* • PCR has a ~3-4 times higher detection rate than culture PCR = polymerase chain reaction; *shedding in the absence of lesions; †shedding rates can vary based upon time since diagnosis, frequency of recurrences, method of detection, frequency/site of sampling Gupta R, et al. J Infect Dis. 2004;190:1374-1381. Wald A, et al. N Engl J Med. 1995;333:770-775. Corey L, et al. N Engl J Med. 2004;350:11-20.

  18. Viral Shedding Patterns Are Unpredictable and Influenced by Therapy Wald A, et al. J Clin Invest. 1997;99:1092-1097.

  19. Up to 70% of Transmission May Occur During Asymptomatic Viral Shedding • 9.7% of patients infected their partner (14/144) • Transmission frequently occurs between outbreaks Transmission during asymptomatic viral shedding Up to 70% ~30% Total 18 17 Transmission during symptomatic outbreaks Mertz GJ, et al. Ann Intern Med. 1992;116:197-202.

  20. Asymptomatic Viral Shedding* Can Occur Regardless of Outbreak Frequency Post-hoc analysis from a randomized, double-blind, placebo-controlled shedding substudy (n = 89) where 50 patients were given placebo once daily and followed for 60 days. Enrolled patients had a history of 0 to 9 recurrences/year and had been infected for a median of 6 years. *Shedding in the absence of lesions. *Shedding in the absence of lesions

  21. Summary of Asymptomatic Viral Shedding • Infection = Shedding • Asymptomatic viral shedding (AVS) is frequent and difficult to predict when and where • AVS does decrease with time but remains high over time • AVS driving force for transmission

  22. Genital Herpes: Diagnosis H. Hunter Handsfield, MD University of Washington

  23. 516 patients with genital ulcer disease from STD clinics in 10 of 11 US cities w/ highest syphilis rates Excluded patients with typical herpes PCR for HSV, Treponema pallidum, Haemophilus ducreyi HSV 333 (64.5%) Syphilis 64 (12.4%) HSV + Syphilis 13 (2.5%) Chancroid 16 (3.1%) PCR negative 16 (22.4%) Etiology of Genital Ulcer Disease Mertz K, et al. J Infect Dis. 1998;178:1795-1798.

  24. Test all genital ulcers for HSV, including clinically obvious genital herpes Clinical diagnosis insensitive and nonspecific Virus type determines clinical prognosis, transmission, and counseling Virologic tests PCR is test of choice; increasingly available Culture: The primary test in most settings Direct FA: Some don't provide virus type Cytology (Tzanck prep): Insensitive, no virus type; do not use Serologic testing: Use only glycoprotein G (gG)-based assays Diagnosis of Genital Herpes

  25. Culture all genital lesions for HSV Obtain TRUST/RPR/EIA HIV Test Negative culture does not rule out HSV May offer Type-specific serologic test North Carolina Dx

  26. Antibody to HSV-1 or -2 glycoprotein G (gG-1 or gG-2) Western blot The gold standard Focus Technologies (now a subsidiary of Quest Diagnostics) HerpeSelect HSV-1 and HSV-2 ELISA Sensitivity for HSV-2 ~90%, specificity ~98% Focus Technologies HerpeSelect HSV-1 and HSV-2 Differentiation Immunoblot Same antigen as ELISA, probably similar performance Trinity Biotech Captia Type Specific HSV-1 nad HSV-2 ELISA Biokit USA biokitHSV2 Point of care HSV-2 only Type-Specific HSV Serologic Tests

  27. The numerical value is the ratio between the test optical density (OD) and control, not a titer ─ <0.9 Negative ─ 0.9–1.1 Equivocal ─ 1.1–3.5 Positive, but influenced by HSV-1 ─ >3.5 Unequivocally positive Notes Varying values below 0.9 are meaningless Some values 1.1–3.5 are false positive if HSV-1 antibody is present Interpreting HSV-2 HerpeSelect

  28. Not type specific Does not distinguish early from late infection False-positive results common There is no valid indication for use in adults HSV IgM Testing is Not Clinically Useful

  29. Western blot Focus immunoblot? Focus ELISA avidity assay? Commercial confirmatory tests (rumors) Focus Others? Repeat/convalescent testing Options for Confirmatory Testingof the Focus HSV-2 ELISA

  30. Time to HSV-2 Seroconversion 1.0 0.8 Western Blot 0.6 Probability of Remaining Seronegative 0.4 Focus 0.2 0.0 0 20 40 60 80 100 120 140 160 Days From Primary Episode

  31. Definite Indications Diagnosis of GUD, recurrent symptoms, etc Management of sex partners of persons with herpes Persons with or at risk for HIV acquisition Other Uses Selected (all?) pregnant women and their partners Patient request Request to test for herpes Comprehensive STD evaluation Do Not Use Routinely to Screen All Sexually Active Persons (controversial) Uses of Type-Specific HSV Serology

  32. Prevention and Available and Emerging Treatments for HSV-2 Infection Peter A. Leone, MD University of North Carolina

  33. Transmission Reduction:What Can Be Done? • Advise patients to avoid sexual contact during outbreaks

  34. Transmission Reduction:What Can Be Done? • Advise patients to avoid sexual contact during outbreaks • Inform patients about transmission risk during periods of asymptomatic shedding

  35. Transmission Reduction:What Can Be Done? • Advise patients to avoid sexual contact during outbreaks • Inform patients about transmission risk during periods of asymptomatic shedding • Offer suppressive therapy to patients as an option

  36. Suppressive Antiviral Therapy to ReduceTransmission Risk

  37. Proportion of Susceptible PartnersWith Overall Acquisition of HSV-2 Infection 3.6% 4 48% reduction P = .054 RR: 0.52 (95% CI: 0.27,0.97) HR for Kaplan-Meyer Analysis P = .039 (27/741) 3 1.9% % with HSV-2 Infection 2 (14/743) 1 0 Placebo Valacyclovir 500 mg once daily Adapted from Corey L, et al. N Engl J Med. 2004;350:11-20.

  38. Proportion of Susceptible PartnersWith Symptomatic Genital Herpes 2.5 2.2% (16/741) 75% reduction 2 P = .01 RR: 0.25 (95% CI: 0.08,0.74) 1.5 % with Symptomatic GH 1 0.5% (4/743) 0.5 0 Placebo Valacyclovir 500 mg once daily Adapted from Corey L, et al. N Engl J Med. 2004;350:11-20.

  39. CDC Sexually Transmitted Diseases Treatment Guidelines and ACOG Recommend Daily Therapy • CDC: Discordant couples should be encouraged to consider suppressive antiviral therapy as a part of a strategy to prevent transmission, in addition to consistent condom use and avoidance of sexual activity during recurrences • ACOG:For couples in which 1 partner has HSV-2 infection, suppressive* antiviral therapy should be recommended for the partner with HSV-2 to reduce the rate of transmission Centers for Disease Control and Prevention. MMWR Recomm Rep. 2006;55(R-11):1-94. *ACOG recommends valacyclovir 500-1000 mg daily for suppressive therapy. ACOG Practice Bulletin. Obstet Gynecol. 2004;104:1111-1117.

  40. Beneficial oral antiviral therapy in first episodes oral antiviral therapy at a start of recurrence daily antiviral therapy to control disease and/or reduce risk of transmission Interventions for HSV Wald, Clinical Evidence ‘99

  41. First clinical episodes of genital herpes All patients Recurrent episodes Clinically significant benefit (20 - 30% decreased duration) from recurrent therapy Prolonged episodes Which Patients Should Receive Episodic Antiviral Therapy?

  42. Self -initiation of therapy important Medication needs to be available to patient Acyclovir can be dosed 3x/day - no clinical trials data, but plenty of experience Optimizing episodic HSV Rx

  43. Acyclovir 400 mg t.i.d. or 200 mg 5 times/d for 7 to 10 days Famciclovir 250 mg t.i.d. for 7 to 10 days Valacyclovir 1 g b.i.d. for 7 to 10 days Initial Episode

  44. Reduces the duration of recurrence Treatment Options:Episodic Therapy 5-Day Shorter Regimens Regimens Acyclovir 400 mg t.i.d. 800 mg t.i.d. for 2 days 800 mg b.i.d. Famciclovir 125 mg b.i.d.1 g b.i.d. for 1 day Valacyclovir 1 g q.d. 500 mg b.i.d. for 3 days Centers for Disease Control and Prevention. MMWR Recomm Rep 2006;55(RR-11):1-93.

  45. Acyclovir 400 mg BID Famciclovir 250 mg BID Valacyclovir 0.5-1.0 g qd North Carolina Offer 4 months suppression with acyclovir to those with documented first episode HSV-2 2006 CDC STD Treatment GuidelinesGenital Herpes: Suppressive Therapy

  46. Candidates for Antiviral Suppressive Therapy

  47. Treatment Options:Suppressive Therapy • Possible dosing regimens¹: • Acyclovir • 400 mg b.i.d. • Famciclovir • 250 mg b.i.d. • Valacyclovir • 500 mg q.d. or (for >10 occurrences/year) • 1 g q.d. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1-78.

  48. Advise patients to avoid sexual contact during outbreaks Inform patients about transmission risk during periods of asymptomatic shedding Offer suppressive therapy to patients as an option Encourage patients to share their HSV status with their sexual partners Promote condom use Transmission Reduction:What Can Be Done?

  49. Transmission Reduction:Disclosure to Sexual Partners • A recent study found that a strong protective factor against genital HSV-2 acquisition was partner disclosure of genital herpes • Median time to transmission nondisclosers: 60 days • vs • disclosers: 270 days P = .03 SHARING Wald A, et al. J Infect Dis. 2006.

  50. Condoms appear ~ 50% protective against HSV-2 acquisition in men and in women. Evidence for condoms' efficacy will always be measured indirectly Condom Sense Wald A, et al. Ann Intern Med 2005;143:707-713. Wald A, et al. JAMA 2001;285:3100-3106. Gottlieb SL, et al. J Infect Dis 2004;190:1059-1067.

More Related